Despite tremendous gains in the molecular understanding of exocrine pancreatic cancer,
the prognosis for this disease remains very poor, largely because of delayed disease …

Pancreatic cancer is one of the solid tumors with the worst prognosis. Five-year survival rate
is less than 10%. Surgical resection is the only potentially curative treatment, but the tumor is …

Thanks to the development of modern chemotherapeutic regimens, survival after surgery for
pancreatic ductal adenocarcinoma (PDAC) has improved and pancreatologists worldwide …

Surgical resection combined with systemic chemotherapy is the cornerstone of treatment for
patients with localized pancreatic cancer. Upfront surgery is considered suboptimal in cases …

Objective: To compare the survival outcomes associated with clinical and pathological
response in pancreatic ductal adenocarcinoma (PDAC) patients receiving neoadjuvant …

Purpose: This study aimed to assess the antitumor activity and safety of neoadjuvant
chemotherapy combined with PD-1 inhibitor camrelizumab in patients with locally advanced …

Purpose: Patient-derived organoids (PDO) are a promising technology to support precision
medicine initiatives for patients with pancreatic ductal adenocarcinoma (PDAC). PDOs may …

Objective: PDAC patients who undergo surgical resection and receive effective
chemotherapy have the best chance of long-term survival. Unfortunately, we lack predictive …

Importance In the past decade, the use of neoadjuvant therapy (NAT) has increased for
patients with borderline and locally advanced pancreatic ductal adenocarcinoma (PDAC) …

Objective: To investigate the outcome of conversion surgery in patients with metastatic
pancreatic cancer (mPDAC) and to identify patients who may benefit from this approach …